Abstract:Background Metagenomic next-generation sequencing (mNGS) is an important supplement to conventional tests for pathogen detections of pneumonia. However, mNGS pipelines were limited by irregularities, high proportion of host nucleic acids, and lack of RNA virus detection. Thus, a regulated pipeline based on mNGS for DNA and RNA pathogen detection of pneumonia is essential. Methods We performed a retrospective study of 151 patients with pneumonia. Three conventional tests, culture, loop-mediated isothermal amplification (LAMP) and viral quantitative real-time polymerase chain reaction (qPCR) were conducted according to clinical needs, and all samples were detected using our optimized pipeline based on the mNGS (DNA and RNA) method. The performances of mNGS and three other tests were compared. Human DNA depletion was achieved respectively by MolYsis kit and pre-treatment using saponin and Turbo DNase. Three RNA library preparation methods were used to compare the detection performance of RNA viruses. Results An optimized mNGS workflow was built, which had only 1-working-day turnaround time. The proportion of host DNA in the pre-treated samples decreased from 99 to 90% and microbiome reads achieved an approximately 20-fold enrichment compared with those without host removal. Meanwhile, saponin and Turbo DNase pre-treatment exhibited an advantage for DNA virus detection compared with MolYsis. Besides, our in-house RNA library preparation procedure showed a more robust RNA virus detection ability. Combining three conventional methods, 76 (76/151, 50.3%) cases had no clear causative pathogen, but 24 probable pathogens were successfully detected in 31 (31/76 = 40.8%) unclear cases using mNGS. The agreement of the mNGS with the culture, LAMP, and viral qPCR was 60%, 82%, and 80%, respectively. Compared with all conventional tests, mNGS had a sensitivity of 70.4%, a specificity of 72.7%, and an overall agreement of 71.5%. Conclusions A complete and effective mNGS workflow was built to provide timely DNA and RNA pathogen detection for pneumonia, which could effectively remove the host sequence, had a higher microbial detection rate and a broader spectrum of pathogens (especially for viruses and some pathogens that are difficult to culture). Despite the advantages, there are many challenges in the clinical application of mNGS, and the mNGS report should be interpreted with caution.

A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification

Rapid Detection of Potential New Pathogens in Patient Using High -Throughput Sequencing

Enhanced DNA and RNA pathogen detection via metagenomic sequencing in patients with pneumonia

A rapid bacterial pathogen and antimicrobial resistance diagnosis workflow using Oxford nanopore adaptive sequencing method

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids

Validation of an unbiased metagenomic detection assay for RNA viruses in viral transport media and plasma

Improved Targeting of the 16S Rdna Nanopore Sequencing Method Enables Rapid Pathogen Identification in Bacterial Pneumonia in Children.

Real-time Utilization of Metagenomic Sequencing in the Diagnosis and Treatment Monitoring of an Invasive Adenovirus B55 Infection and Subsequent Herpes Simplex Virus Encephalitis in an Immunocompetent Young Adult.

Unbiased metagenomic detection of RNA viruses for rapid identification of viral pathogens in clinical samples

Unified metagenomic method for rapid detection of microorganisms in clinical samples

Targeting RNA with Next‐ and Third‐Generation Sequencing Improves Pathogen Identification in Clinical Samples

Rapid metagenomic identification of two major swine pathogens with real-time nanopore sequencing.

Nanopore sequencing of infectious fluid is a promising supplement for gold-standard culture in real-world clinical scenario

Metagenomic next-generation sequencing testing from the perspective of clinical benefits

High-Throughput Metagenomics for Identification of Pathogens in the Clinical Settings

Towards a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow on the Illumina Platforms

Validation of an automated, end-to-end metagenomic sequencing assay for agnostic detection of respiratory viruses

Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery

Retrospective Validation of a Metagenomic Sequencing Protocol for Combined Detection of RNA and DNA Viruses Using Respiratory Samples from Pediatric Patients

A Dual-Process of Targeted and Unbiased Nanopore Sequencing Enables Accurate and Rapid Diagnosis of Lower Respiratory Infections